NCT01585649CompletedPhase 1
Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Merckle GmbH
- Enrollment
- 21
- Locations
- 18
- Primary Endpoint
- PK: Area under the curve, Maximum observed serum concentration (Cmax), Rate constant associated with terminal phase, Mean Residence Time, Time to reach Cmax, and Apparent volume of distribution during terminal phase after non-intravenous administration
Study Overview
Brief Summary
This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma scheduled to receive chemotherapy (CTX)
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 2 Years to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female children and adolescents aged 2 to <18 years
- •Written informed consent provided by parent(s)/legal representative(s) of the pediatric patient and patient's assent if appropriate
- •Able to understand and/or follow study instructions alone or with parental assistance
- •Diagnosed with the Ewing family of tumors or Rhabdomyosarcoma
- •Scheduled to receive 1 of the following CTX regimens (inpatient or outpatient)
- •For the Ewing family of tumors:
- •vincristine/ifosfamide/doxorubicin/etoposide (VIDE); with concomitant sodium 2-mercaptoethane sulfonate (MESNA) according to local standards
- •vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
- •For rhabdomyosarcoma:
- •vincristine/actinomycin/cyclophosphamide (VAC)
- •vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
- •Chemotherapy-naïve
- •Body weight ≥15 kg
- •White blood cell (WBC) count >2.5 x 109/L, absolute neutrophil count (ANC) ≥1.5 x 109/L, and platelet count ≥100 x 109/L (at screening and prior to CTX)
- •For patients aged ≥12 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (See Appendix A.)
- •Fertile patients (male or female) must use highly reliable contraceptive measures (i.e. two of the following: oral contraception, implants, injections, barrier contraception, and intrauterine device, or vasectomized/sterilized partners, or sexual abstinence). For purposes of this study, a fertile female patient is any female patient who has experienced menarche and who has not undergone tubal ligation.
- •Female patients who have attained menarche must have a negative urine pregnancy test at the screening visit.
Exclusion Criteria
- •Previous exposure to filgrastim, pegfilgrastim or lenograstim or other G-CSFs in clinical development within 6 months prior to the XM22 administration
- •Known hypersensitivity to filgrastim, pegfilgrastim or lenograstim or any other G-CSF in clinical development
- •History of congenital neutropenia or cyclic neutropenia
- •Any illness or condition that in the opinion of the Investigator may affect the safety of the patient or the evaluation of any study endpoint
- •Pregnant or nursing women
- •Fertile patients who do not agree to use highly reliable contraceptive measures during the entire duration of the study
- •Prior bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow (e.g. whole pelvic radiation) for any reason, or any therapeutic radiation within the 3 weeks prior to the XM22 dose
- •Ongoing active infection or history of infectious disease within 2 weeks prior to the screening visit
- •Treatment with lithium at screening or planned during the study.
Arms & Interventions
XM22, 100 μg/kg BW
Experimental
Intervention: Lipegfilgrastim (Drug)
Outcomes
Primary Outcomes
PK: Area under the curve, Maximum observed serum concentration (Cmax), Rate constant associated with terminal phase, Mean Residence Time, Time to reach Cmax, and Apparent volume of distribution during terminal phase after non-intravenous administration
Time Frame: 16 months
A total of 7 PK samples will be obtained at prespecified periods
Secondary Outcomes
- PD:Absolute Neutrophil Count(16 months)
Investigators
Study Sites (18)
Loading locations...
Similar Trials
Completed
Phase 1
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT02825940Hoffmann-La Roche120
Completed
Phase 1
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.Parkinson DiseaseNCT03496870Neurocrine Biosciences16
Active, not recruiting
Phase 1
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Advanced Solid TumorNCT06421935EMD Serono Research & Development Institute, Inc.60
Completed
Phase 1
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With HemophiliaHemophilia A With InhibitorHemophilia B With InhibitorHemophilia A Without InhibitorHemophilia B Without InhibitorHemophilia AHemophilia BNCT04072237Catalyst Biosciences11
Recruiting
Phase 1
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) TherapyNon-Muscle-Invasive Bladder Cancer (NMIBC)NCT06351904Ractigen Therapeutics.72